Tandem Meetings 2023 | The role of elotuzumab-based combinations in multiple myeloma therapy
Michael Slade
• 15 Feb 2023
Michael Slade, MD, Washington University School of Medicine, St Louis, MO, talks on the role of elotuzumab-based therapies in multiple myeloma, explaining that its place in the treatment algorithm of multiple myeloma remains unclear. Nevertheless, anecdotal evidence suggests that elotuzumab-based triplet combinations appear to be more beneficial in patients with slowly progressing disease. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
